The abstracts of the CTAD are available in PDF format, you can download them on
this link
The abstracts of the ICFSR are available in PDF format, you can download them on this link
this link
The abstracts of the ICFSR are available in PDF format, you can download them on this link
this link
Randomized placebo-controlled trials in the development of disease-modifying treatments for Alzheimer’s disease are typically of short duration (12–18 months), and health economic modeling requires extrapolation of treatment effects beyond the trial period. (1) Reed, C., Happich, M., Raskin, J. et al…. Continue Reading →
Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and… Continue Reading →
Following the press release issued by Biogen regarding their plans on regulatory filing for Aducanumab in Alzheimer’s disease based on new analysis of larger dataset from Phase 3 studies, we are pleased to announce that these results will be presented… Continue Reading →
© 2024 Aging-news
